Figures & data
Figure 1 Representation of the three anti-CD20 monoclonal antibodies: rituximab, ocrelizumab, and ofatumumab.
Figure 2 B-cell lines that are targeted and spared by the action of ocrelizumab.
Figure 3 Mechanism of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
Abbreviaiton: MAC, membrane attack complex.
